Lead Product(s): 4D-110
Therapeutic Area: Ophthalmology Product Name: 4D-110
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 4D Molecular Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination June 24, 2021
Roche requested that 4DMT conclude the Roche-funded 4D-110 trial in advanced choroideremia patients as a result of Roche’s assessment of a change in the risk-benefit profile.